The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
C | Cardiovascular system | |
2
|
C09 | Agents acting on the renin-angiotensin system | |
3
|
C09D | Angiotensin II antagonists, combinations | |
4
|
C09DA | Angiotensin II antagonists and diuretics | |
5
|
C09DA04 | Irbesartan and diuretics |
| Active Ingredient |
|---|
|
The combination of irbesartan and hydrochlorothiazide has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone. Irbesartan is a potent, orally active, selective angiotensin-II receptor (AT1 subtype) antagonist. Hydrochlorothiazide is a thiazide diuretic. The combination of hydrochlorothiazide and irbesartan produces dose-related additive reductions in blood pressure across their therapeutic dose ranges. |
| Document | Type | Information Source | |
|---|---|---|---|
| COAPROVEL Tablet | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.